An observational study in Asthma Acute, Asthma Childhood and Asthma in Children, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 2 sites in Italy. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Meyer Children's Hospital IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.
Among the 177 studies in Asthma with a site in Italy, this one is the 15th largest by planned enrollment of the 47 observational ones that give a count, is one of 7 that started in 2025, is one of 47 observational ones, reaches primary completion later than 7 of the 28 other live ones, and was the 172nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 6+
Generate Biomedicines · Sites in Italy, United States, Argentina and 16 more countries
Ages 12–80
Pfizer · Sites in Italy, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Italy, United States, Argentina and 18 more countries
Ages 18–75
GlaxoSmithKline · Sites in Italy, United States, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 402 across the 130 interventional studies, 152 across the 47 observational. Of the 136 that completed or were terminated, 66 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 177 have an industry lead sponsor. The 10 most frequent:
Meyer Children's Hospital IRCCS is the lead sponsor of 79 studies on the registry; 56 are open to participants now.
Meyer Children's Hospital IRCCS has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT04442646Istituti Clinici Scientifici Maugeri SpARole of "Asthma School" in Disease Management | 2026-12-15 |
| NCT06625216Società Italiana di Allergologia, Asma e Immunologia ClinicaSevere Asthma Network Italy | 2027-02-17 |
Add all 10 to your calendar (.ics) → With an account.
Among the 177 studies in Asthma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.
Patients aged 6 to 17 years presenting to the emergency department with an acute asthma exacerbation were included. Clinical outcomes were compared between a pre-intervention period (October 2024-May 2025) and a post-intervention period (October 2025-May 2026).
Between the two study periods, a structured educational intervention targeting medical and nursing staff was implemented. The intervention consisted of didactic lectures, clinical simulation sessions, case-based discussions, and the dissemination of updated diagnostic and therapeutic flowcharts based on the 2025 Global Initiative for Asthma (GINA) guidelines.
The study population consists of pediatric patients aged 6 to 17 years presenting to the emergency departments of two Italian tertiary-care hospitals (AOU IRCCS Meyer Children's Hospital in Florence and Arcispedale S. Anna in Ferrara) with an acute asthma exacerbation.
Eligible patients were identified through retrospective review of electronic medical records of all emergency department visits occurring during the predefined study periods. Patients were included if they received a discharge diagnosis consistent with acute asthma exacerbation or related conditions (e.g., bronchospasm, asthma attack, asthmatic bronchitis, wheezing).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric patients aged 6-17 years presenting to the emergency department with an acute asthma exacerbation during the pre-intervention period (October 2024-May 2025). Patients received standard care according to local clinical practice prior to the implementation of the structured educational intervention. Intervention: No intervention (standard of care)
Pediatric patients aged 6-17 years presenting to the emergency department with an acute asthma exacerbation during the post-intervention period (October 2025-May 2026), after the implementation of a structured educational intervention for emergency department staff. Intervention: Educational intervention (health care provider-directed)
Change in the number of correctly reported diagnoses before and after intervention
Assessment of adherence to guideline-based diagnostic and therapeutic management of pediatric patients presenting with acute asthma exacerbations in the emergency department.
Time frame: Pre-intervention and through study completion, an average of 9 months
Percentage of patients with correct timing, dosage, and method of drug administration before and after intervention
Time frame: Pre-intervention and through study completion, an average of 9 months
Percentage of patients with correct follow-up at discharge
Time frame: Pre-intervention and through study completion, an average of 9 months
Percentage of patients in whom additional drugs are used in refractory cases
Time frame: Pre-intervention and through study completion, an average of 9 months
Percentage of patients with correct therapy at discharge
Time frame: Pre-intervention and through study completion, an average of 9 months
Incidence of acute asthma exacerbations
Number of emergency department visits for acute asthma exacerbations among pediatric patients during the pre- and post-intervention periods.
Time frame: Pre-intervention and through study completion, an average of 9 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2026, 6 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 6 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meyer Children's Hospital IRCCS